CTLA4-Ig gene therapy

Drug Profile

CTLA4-Ig gene therapy

Alternative Names: AdCTLA4Ig

Latest Information Update: 20 Jul 2006

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Gene therapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Heart transplant rejection; Lung transplant rejection; Rheumatoid arthritis

Most Recent Events

  • 20 Jul 2006 No development reported - Preclinical for Lung transplant rejection in Japan (unspecified route)
  • 16 Apr 2003 A preclinical study has been added to the Transplant rejection pharmacodynamics section
  • 10 Mar 2003 Preclinical trials in Lung transplant rejection in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top